Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 408Rectal Neoplasms 152Colonic Neoplasms 150Pancreatic Neoplasms 114Stomach Neoplasms 110Neoplasm Metastasis 70Esophageal Neoplasms 60Esophageal Squamous Cell Carcinoma 33Neoplasms 31Adenocarcinoma Of Esophagus 27Gastrointestinal Neoplasms 17Cholangiocarcinoma 14Biliary Tract Neoplasms 14Gallbladder Neoplasms 12Carcinoma, Hepatocellular 12Adenocarcinoma 12Colorectal Cancer Metastatic 11Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 11Liver Neoplasms 10Digestive System Neoplasms 10Ovarian Neoplasms 9Small Cell Lung Carcinoma 8Locally Advanced Rectal Cancer 8Intestinal Neoplasms 8Bile Duct Neoplasms 8Carcinoma 7Parkinson Disease 4, Autosomal Dominant Lewy Body 6Digestive System Diseases 6Appendiceal Neoplasms 6

Interventions

Gemcitabine 4130-nm albumin-bound paclitaxel 2sintilimab 1nimotuzumab 1avelumab 1Taxes 1Oxaliplatin 1Leucovorin 1Irinotecan 1Hydroxychloroquine 1Fluorouracil 1Capecitabine 1Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Cancer Resectable × Irinotecan × Gastrointestinal × Clear all
NCT07155629 2025-09-04

LEFT-PANC

Helsinki University Central Hospital

Phase 3 Not yet recruiting
381 enrolled
Gastrointestinal

Pancreatic Cancer Resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡